. A schema of the Hh signaling pathway and smoothened (SMO) inhibitor. Figure S2 . Ki-67 immunostaining of bone marrow samples derived from AML patients in treatment with PF-913. Stained cells were photographed using a 10× objective lens on an HS All-in-one Fluorescence Microscope BZ-X710 (Keyence, Osaka, Japan), and then analyzed with BZ-X Analyzer software 1.3.0.3 (Keyence). Scale bar indicates 100 µm. AML cells taken from patients on day 5 were stained more strongly than control cells. The proportion of stained cells within samples decreased on week 2 and 4.
. A schema of the Hh signaling pathway and smoothened (SMO) inhibitor. Figure S2 . Ki-67 immunostaining of bone marrow samples derived from AML patients in treatment with PF-913. Stained cells were photographed using a 10× objective lens on an HS All-in-one Fluorescence Microscope BZ-X710 (Keyence, Osaka, Japan), and then analyzed with BZ-X Analyzer software 1.3.0.3 (Keyence). Scale bar indicates 100 µm. AML cells taken from patients on day 5 were stained more strongly than control cells. The proportion of stained cells within samples decreased on week 2 and 4. Figure S3 . Gene profile analysis showed us that some of cell-cycle associated molecules were down-regulated comparing the samples of 2 weeks after treatment with those of pre-treatment among three patients. Figure S4 . Immunostaining of patients' bone marrow samples with NANOG antibody. The proportions of stained area decreased during treatment with PF-913. Scale bar indicates 10 µm.
